Navigation Links
Dr. James F. Pingpank to Present at the Sixth International Symposium on Melanoma and Other Cutaneous Malignancies on March 13- 14, 2009 in New York City

NEW YORK, March 12 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for the treatment of cancers of the liver, announced today that Dr. James F. Pingpank will present at The Sixth International Symposium on Melanoma, to be held in New York City on March 13-14, 2009.


Dr. Pingpank's presentation is titled Targeting the Liver: Percutaneous Hepatic Perfusion/Intra-Arterial. Dr. Pingpank will discuss his experience with The Delcath PHP System(TM) and the Company's Phase III Metastatic Melanoma Study, currently enrolling at eleven leading cancer centers throughout the United States.

The Phase III clinical study is being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. This clinical study is testing the Delcath PHP System(TM) for the regional delivery of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver. The Delcath PHP System(TM) is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while minimizing entry of the drugs into the rest of the patient's circulation. This isolation limits toxicities which result from systemic chemotherapy treatments.

Patients in the Phase III trial are randomized into one of two treatment arms, including immediate treatment with melphalan via the Delcath PHP System(TM) or treatment with best alternative care. The study is designed to evaluate the duration of tumor response in each of the two study arms. Following guidelines established by U.S. Food and Drug Administration under a Special Protocol Assessment (SPA), patients are permitted to "cross-over" from the best alternative care arm to receive treatment with the Delcath System at the time of disease progression.

Commenting on Dr. Pingpank's upcoming presentation, Richard L. Taney, President and CEO of Delcath Systems, stated, "Delcath's pivotal Phase III Metastatic Melanoma Study has experienced significant momentum over the past six months, and this presentation is another important opportunity for Delcath to communicate our experience to the medical and surgical oncology communities. Both Dr. Sanjiv Agarwala, Program Chair of the conference, and Dr. Pingpank, have significant experience with The Delcath PHP System(TM) and, we look forward to future opportunities like these to update the physician and medical communities on the potential of this technology."

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Veteran Rehab Specialist, James Conwell, Joins Fast-Growing Alliance Seating & Mobility in Pennsylvania
2. NutraCea Names James C. Lintzenich As Interim CEO
3. Thoratec Presentation at Raymond James Conference to Be Webcast
4. MedCath Corporation to Present at the Raymond James & Associates 30th Annual Institutional Investors Conference
5. PAREXEL International to Present at Raymond James 30th Annual Institutional Investors and the Barclays Capital Global Healthcare Conferences
6. Aflac Incorporated To Present at the Raymond James 30th Annual Institutional Investors Conference
7. LCA-Vision to Present at the Raymond James 30th Annual Institutional Investors Conference
8. CVS Caremark Corporation to Present at the Raymond James Institutional Investors Conference on March 10th
9. Command Medical Products, Inc. Welcomes James Carnall
10. Senator James Sasser, Former Ambassador to China, Joins Neuralstem Advisory Board
11. James Roosevelt, Jr. Joins Inverness Medical Innovations Board of Directors
Post Your Comments:
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology: